EMYRIA LIMITED - Announcements

6.52%

4.9¢

Market Cap $29.96M

Healthcare Biotechnology

Emyria Limited is an Australia-based early-stage drug development company. The Company is... Emyria Limited is an Australia-based early-stage drug development company. The Company is focused on delivering and developing treatments for mental health and select neurological conditions, guided by real-world data collected with patients across its wholly owned clinical service subsidiaries. Its pipeline comprises MDMA analogue drug development and commercialization of novel serotonin-releasing agents. Its Emyria Healthcare provides evidence-based treatment for patients not finding relief from conventional care, while also helping evaluate emerging new therapies like assisted therapy for post-traumatic stress disorder (PTSD) and assisted therapy for treatment-resistant depression. Its Emyria Data is a robust and ethically sourced real-world data gathered with patients and used to improve its therapy and drug development programs. Its Emyria’s Pipeline includes new psychedelic-assisted therapies and drug treatments for mental health and select neurological diseases.More

HELPING PATIENTS ON THEIR JOURNEY TO BETTER HEALTH

Little Green Pharma (ASX:LGP) to benefit as Denmark commits to cannabis pilot program.

Announcements

Filter Results

All Price Sensitive Only

EMD	Notification regarding unquoted securities - EMD		25/11/22	27.34KB	Share
EMD	Placement completion and secondary trading notice	PRICE SENSITIVE	23/11/22	526.8KB	Share
EMD	Investor Presentation		23/11/22	9.99MB	Share
EMD	Notification regarding unquoted securities - EMD		23/11/22	30.31KB	Share
EMD	Application for quotation of securities - EMD		23/11/22	26.45KB	Share
EMD	Notification of cessation of securities - EMD		18/11/22	22.68KB	Share
EMD	Amended Constitution		17/11/22	525.89KB	Share
EMD	Appendix 4C - Quarterly	PRICE SENSITIVE	31/10/22	861.3KB	Share
EMD	Proposed issue of securities - EMD		31/10/22	29.29KB	Share
EMD	Proposed issue of securities - EMD		31/10/22	28.32KB	Share
EMD	Proposed issue of securities - EMD		31/10/22	27.05KB	Share
EMD	Emyria completes $3m placement	PRICE SENSITIVE	31/10/22	540.33KB	Share
EMD	Trading Halt	PRICE SENSITIVE	27/10/22	675.01KB	Share
EMD	Results of Meeting		25/10/22	533.44KB	Share
EMD	Emyria and UWA expand unique MDMA-inspired analogue library	PRICE SENSITIVE	18/10/22	535.12KB	Share
EMD	MDMA-inspired drug discovery presentation		13/10/22	5.3MB	Share
EMD	Emyria Investor Webinar - October 13		10/10/22	316.84KB	Share
EMD	Emyria expands clinical sites for EMD-RX5 Phase 3 trial	PRICE SENSITIVE	26/09/22	306.61KB	Share
EMD	Letter to Shareholders - Annual General Meeting		23/09/22	868.92KB	Share
EMD	Notice of Annual General Meeting/Proxy Form		23/09/22	1.05MB	Share
EMD	Emyria commences US preclinical program for MDMA library	PRICE SENSITIVE	19/09/22	524.42KB	Share
EMD	Annual General Meeting		31/08/22	286.76KB	Share
EMD	Annual Report to Shareholders		30/08/22	1.61MB	Share
EMD	Appendix 4G		29/08/22	286.48KB	Share
EMD	Appendix 4E and Annual Report	PRICE SENSITIVE	29/08/22	1.78MB	Share
EMD	Positive results received for Emyrias MDMA-inspired program	PRICE SENSITIVE	18/08/22	315.32KB	Share
EMD	Notification regarding unquoted securities - EMD		17/08/22	30.11KB	Share
EMD	Emyria receives ethics approval for EMD-RX5 Phase 3 trial	PRICE SENSITIVE	16/08/22	155.53KB	Share
EMD	Preclinical studies initiated for MDMA-inspired analogues	PRICE SENSITIVE	04/08/22	157.16KB	Share
EMD	Appendix 4C - Quarterly	PRICE SENSITIVE	28/07/22	776.97KB	Share
EMD	Emyria expands drug candidate library inspired by MDMA	PRICE SENSITIVE	18/07/22	161.97KB	Share
EMD	Notification regarding unquoted securities - EMD		09/06/22	30.11KB	Share
EMD	Drug development webinar presentation		01/06/22	6.77MB	Share
EMD	Emyria expands MDMA analogue program with UWA	PRICE SENSITIVE	31/05/22	1.13MB	Share
EMD	Emyria Investor Webinar, June 1st		30/05/22	143.96KB	Share
EMD	EMD-RX5 demonstrates excellent safety and bioavailability	PRICE SENSITIVE	25/05/22	1.17MB	Share
EMD	Trading Halt	PRICE SENSITIVE	23/05/22	242.03KB	Share
EMD	Further positive MDMA analogue screening results received	PRICE SENSITIVE	10/05/22	691.73KB	Share
EMD	Appendix 4C - Quarterly	PRICE SENSITIVE	27/04/22	965.14KB	Share
EMD	Results of Meeting		20/04/22	128.67KB	Share
EMD	Change of Director's Interest Notice MW		20/04/22	240.42KB	Share
EMD	EMD-RX5 Dosing to Complete for Phase 1 Clinical Trial		14/04/22	453.07KB	Share
EMD	Clinitrials to lead multi-site Phase 3 trial for EMD-RX5		13/04/22	145.67KB	Share
EMD	Dosing Commences For EMD-RX5 Phase 1 Human Clinical Trial		07/04/22	453.01KB	Share
EMD	Broker Briefing Presentation		24/03/22	6.97MB	Share
EMD	Emyria to present webinar, March 24th		23/03/22	143.73KB	Share
EMD	Letter to Shareholders - Adjourned General Meeting		18/03/22	890.21KB	Share
EMD	Addendum to Notice of Meeting and Proxy Form		18/03/22	808.77KB	Share
EMD	Emyria launches second ultra-pure CBD capsule	PRICE SENSITIVE	17/03/22	255.24KB	Share
EMD	EMD-RX5 program advancing Phase 1 clinical trials underway	PRICE SENSITIVE	17/03/22	255.24KB	Share
EMD	Recruitment commenced for EMD-RX5 Phase 1 Study	PRICE SENSITIVE	09/03/22	134.96KB	Share
EMD	Hidden Gems Webinar Presentation		04/03/22	5.28MB	Share
EMD	Ethics approval received for EMD-RX5 Phase 1 Study	PRICE SENSITIVE	03/03/22	135.53KB	Share
EMD	Emyria to present at Hidden Gems Webinar March 4th		02/03/22	138.09KB	Share
EMD	Half Yearly Report and Accounts	PRICE SENSITIVE	28/02/22	990.39KB	Share
EMD	Emyria grows its novel MDMA-analogue library	PRICE SENSITIVE	22/02/22	138.19KB	Share
EMD	General Meeting Adjourned - Letter to Shareholders		22/02/22	232.43KB	Share
EMD	Application for quotation of securities - EMD		14/02/22	25.99KB	Share
EMD	Release of securities from escrow		04/02/22	265.44KB	Share
EMD	Notice under section 708A(5)(e) of the Corporations Act		28/01/22	278.64KB	Share
EMD	Application for quotation of securities - EMD		28/01/22	26.54KB	Share
EMD	Appendix 4C - Quarterly	PRICE SENSITIVE	28/01/22	590.41KB	Share
EMD	Letter to Shareholders - General Meeting		21/01/22	872.16KB	Share
EMD	Notice of General Meeting/Proxy Form		21/01/22	838.71KB	Share
EMD	Phase 1 trial commences Q1, 2022 for Emyrias ultra-pure CBD	PRICE SENSITIVE	20/01/22	269.86KB	Share
EMD	Notification regarding unquoted securities - EMD		31/12/21	29.19KB	Share
EMD	Proposed issue of securities - EMD		30/12/21	25.53KB	Share
EMD	Emyria appoints Sixty Two Capital as corporate advisor		30/12/21	141.25KB	Share
EMD	Notice under section 708A(5)(e) of the Corporations Act		23/12/21	314.42KB	Share
EMD	Application for quotation of securities - EMD		23/12/21	26.51KB	Share
EMD	Change of Registry Address		20/12/21	152.9KB	Share
EMD	Emyria adds wearables to psychedelic-assisted therapy trials	PRICE SENSITIVE	20/12/21	167.02KB	Share
EMD	Trading Halt	PRICE SENSITIVE	16/12/21	696.42KB	Share
EMD	Pause in Trading	PRICE SENSITIVE	16/12/21	115.5KB	Share
EMD	Positive animal data for Emyrias ultra-pure CBD capsule	PRICE SENSITIVE	15/12/21	236.96KB	Share
EMD	Positive initial MDMA-analogue screening results	PRICE SENSITIVE	08/12/21	145.86KB	Share
EMD	Change of Director's Interest Notice KS		07/12/21	239.22KB	Share
EMD	Application for quotation of securities - EMD		06/12/21	29.04KB	Share
EMD	Notice under section 708A(5)(e) of the Corporations Act		01/12/21	314.12KB	Share
EMD	Application for quotation of securities - EMD		01/12/21	26.51KB	Share
EMD	Application for quotation of securities - EMD		01/12/21	26.76KB	Share
EMD	Initial Director's Interest Notice KS		30/11/21	133.33KB	Share
EMD	Emyria Appoints Global Pharma Expert Dr Karen Smith to Board		29/11/21	163.93KB	Share
EMD	Emyria Anoints Global Pharma Expert Dr Karen Smith to Board		29/11/21	163.93KB	Share
EMD	Change in substantial holding SW		26/11/21	110.15KB	Share
EMD	Change in substantial holding MW		26/11/21	134KB	Share
EMD	Change in substantial holding MT		26/11/21	102.7KB	Share
EMD	Change in substantial holding CD		26/11/21	104.77KB	Share
EMD	Becoming a substantial holder TAT		25/11/21	97.09KB	Share
EMD	Notification regarding unquoted securities - EMD		24/11/21	29.1KB	Share
EMD	Application for quotation of securities - EMD		24/11/21	26.5KB	Share
EMD	Notice under section 708A(5)(e) of the Corporations Act		24/11/21	314.84KB	Share
EMD	Emyria receives $1,162,000 R&D Tax Incentive Refund	PRICE SENSITIVE	24/11/21	141.05KB	Share
EMD	Application for quotation of securities - EMD		22/11/21	26.69KB	Share
EMD	Proposed issue of securities - EMD		22/11/21	28.34KB	Share
EMD	Emyria Welcomes Tattarang as Strategic Investor	PRICE SENSITIVE	22/11/21	230.86KB	Share
EMD	Trading Halt	PRICE SENSITIVE	19/11/21	702.94KB	Share
EMD	Results of Meeting		03/11/21	146.11KB	Share
EMD	Notification regarding unquoted securities - EMD		01/11/21	28.32KB	Share
EMD	Appendix 4C - Quarterly	PRICE SENSITIVE	26/10/21	327.47KB	Share

EMD Notification regarding unquoted securities - EMD
25/11/22		27.34KB	Share
EMD Placement completion and secondary trading notice
23/11/22	PRICE SENSITIVE	526.8KB	Share
EMD Investor Presentation
23/11/22		9.99MB	Share
EMD Notification regarding unquoted securities - EMD
23/11/22		30.31KB	Share
EMD Application for quotation of securities - EMD
23/11/22		26.45KB	Share
EMD Notification of cessation of securities - EMD
18/11/22		22.68KB	Share
EMD Amended Constitution
17/11/22		525.89KB	Share
EMD Appendix 4C - Quarterly
31/10/22	PRICE SENSITIVE	861.3KB	Share
EMD Proposed issue of securities - EMD
31/10/22		29.29KB	Share
EMD Proposed issue of securities - EMD
31/10/22		28.32KB	Share
EMD Proposed issue of securities - EMD
31/10/22		27.05KB	Share
EMD Emyria completes $3m placement
31/10/22	PRICE SENSITIVE	540.33KB	Share
EMD Trading Halt
27/10/22	PRICE SENSITIVE	675.01KB	Share
EMD Results of Meeting
25/10/22		533.44KB	Share
EMD Emyria and UWA expand unique MDMA-inspired analogue library
18/10/22	PRICE SENSITIVE	535.12KB	Share
EMD MDMA-inspired drug discovery presentation
13/10/22		5.3MB	Share
EMD Emyria Investor Webinar - October 13
10/10/22		316.84KB	Share
EMD Emyria expands clinical sites for EMD-RX5 Phase 3 trial
26/09/22	PRICE SENSITIVE	306.61KB	Share
EMD Letter to Shareholders - Annual General Meeting
23/09/22		868.92KB	Share
EMD Notice of Annual General Meeting/Proxy Form
23/09/22		1.05MB	Share
EMD Emyria commences US preclinical program for MDMA library
19/09/22	PRICE SENSITIVE	524.42KB	Share
EMD Annual General Meeting
31/08/22		286.76KB	Share
EMD Annual Report to Shareholders
30/08/22		1.61MB	Share
EMD Appendix 4G
29/08/22		286.48KB	Share
EMD Appendix 4E and Annual Report
29/08/22	PRICE SENSITIVE	1.78MB	Share
EMD Positive results received for Emyrias MDMA-inspired program
18/08/22	PRICE SENSITIVE	315.32KB	Share
EMD Notification regarding unquoted securities - EMD
17/08/22		30.11KB	Share
EMD Emyria receives ethics approval for EMD-RX5 Phase 3 trial
16/08/22	PRICE SENSITIVE	155.53KB	Share
EMD Preclinical studies initiated for MDMA-inspired analogues
04/08/22	PRICE SENSITIVE	157.16KB	Share
EMD Appendix 4C - Quarterly
28/07/22	PRICE SENSITIVE	776.97KB	Share
EMD Emyria expands drug candidate library inspired by MDMA
18/07/22	PRICE SENSITIVE	161.97KB	Share
EMD Notification regarding unquoted securities - EMD
09/06/22		30.11KB	Share
EMD Drug development webinar presentation
01/06/22		6.77MB	Share
EMD Emyria expands MDMA analogue program with UWA
31/05/22	PRICE SENSITIVE	1.13MB	Share
EMD Emyria Investor Webinar, June 1st
30/05/22		143.96KB	Share
EMD EMD-RX5 demonstrates excellent safety and bioavailability
25/05/22	PRICE SENSITIVE	1.17MB	Share
EMD Trading Halt
23/05/22	PRICE SENSITIVE	242.03KB	Share
EMD Further positive MDMA analogue screening results received
10/05/22	PRICE SENSITIVE	691.73KB	Share
EMD Appendix 4C - Quarterly
27/04/22	PRICE SENSITIVE	965.14KB	Share
EMD Results of Meeting
20/04/22		128.67KB	Share
EMD Change of Director's Interest Notice MW
20/04/22		240.42KB	Share
EMD EMD-RX5 Dosing to Complete for Phase 1 Clinical Trial
14/04/22		453.07KB	Share
EMD Clinitrials to lead multi-site Phase 3 trial for EMD-RX5
13/04/22		145.67KB	Share
EMD Dosing Commences For EMD-RX5 Phase 1 Human Clinical Trial
07/04/22		453.01KB	Share
EMD Broker Briefing Presentation
24/03/22		6.97MB	Share
EMD Emyria to present webinar, March 24th
23/03/22		143.73KB	Share
EMD Letter to Shareholders - Adjourned General Meeting
18/03/22		890.21KB	Share
EMD Addendum to Notice of Meeting and Proxy Form
18/03/22		808.77KB	Share
EMD Emyria launches second ultra-pure CBD capsule
17/03/22	PRICE SENSITIVE	255.24KB	Share
EMD EMD-RX5 program advancing Phase 1 clinical trials underway
17/03/22	PRICE SENSITIVE	255.24KB	Share
EMD Recruitment commenced for EMD-RX5 Phase 1 Study
09/03/22	PRICE SENSITIVE	134.96KB	Share
EMD Hidden Gems Webinar Presentation
04/03/22		5.28MB	Share
EMD Ethics approval received for EMD-RX5 Phase 1 Study
03/03/22	PRICE SENSITIVE	135.53KB	Share
EMD Emyria to present at Hidden Gems Webinar March 4th
02/03/22		138.09KB	Share
EMD Half Yearly Report and Accounts
28/02/22	PRICE SENSITIVE	990.39KB	Share
EMD Emyria grows its novel MDMA-analogue library
22/02/22	PRICE SENSITIVE	138.19KB	Share
EMD General Meeting Adjourned - Letter to Shareholders
22/02/22		232.43KB	Share
EMD Application for quotation of securities - EMD
14/02/22		25.99KB	Share
EMD Release of securities from escrow
04/02/22		265.44KB	Share
EMD Notice under section 708A(5)(e) of the Corporations Act
28/01/22		278.64KB	Share
EMD Application for quotation of securities - EMD
28/01/22		26.54KB	Share
EMD Appendix 4C - Quarterly
28/01/22	PRICE SENSITIVE	590.41KB	Share
EMD Letter to Shareholders - General Meeting
21/01/22		872.16KB	Share
EMD Notice of General Meeting/Proxy Form
21/01/22		838.71KB	Share
EMD Phase 1 trial commences Q1, 2022 for Emyrias ultra-pure CBD
20/01/22	PRICE SENSITIVE	269.86KB	Share
EMD Notification regarding unquoted securities - EMD
31/12/21		29.19KB	Share
EMD Proposed issue of securities - EMD
30/12/21		25.53KB	Share
EMD Emyria appoints Sixty Two Capital as corporate advisor
30/12/21		141.25KB	Share
EMD Notice under section 708A(5)(e) of the Corporations Act
23/12/21		314.42KB	Share
EMD Application for quotation of securities - EMD
23/12/21		26.51KB	Share
EMD Change of Registry Address
20/12/21		152.9KB	Share
EMD Emyria adds wearables to psychedelic-assisted therapy trials
20/12/21	PRICE SENSITIVE	167.02KB	Share
EMD Trading Halt
16/12/21	PRICE SENSITIVE	696.42KB	Share
EMD Pause in Trading
16/12/21	PRICE SENSITIVE	115.5KB	Share
EMD Positive animal data for Emyrias ultra-pure CBD capsule
15/12/21	PRICE SENSITIVE	236.96KB	Share
EMD Positive initial MDMA-analogue screening results
08/12/21	PRICE SENSITIVE	145.86KB	Share
EMD Change of Director's Interest Notice KS
07/12/21		239.22KB	Share
EMD Application for quotation of securities - EMD
06/12/21		29.04KB	Share
EMD Notice under section 708A(5)(e) of the Corporations Act
01/12/21		314.12KB	Share
EMD Application for quotation of securities - EMD
01/12/21		26.51KB	Share
EMD Application for quotation of securities - EMD
01/12/21		26.76KB	Share
EMD Initial Director's Interest Notice KS
30/11/21		133.33KB	Share
EMD Emyria Appoints Global Pharma Expert Dr Karen Smith to Board
29/11/21		163.93KB	Share
EMD Emyria Anoints Global Pharma Expert Dr Karen Smith to Board
29/11/21		163.93KB	Share
EMD Change in substantial holding SW
26/11/21		110.15KB	Share
EMD Change in substantial holding MW
26/11/21		134KB	Share
EMD Change in substantial holding MT
26/11/21		102.7KB	Share
EMD Change in substantial holding CD
26/11/21		104.77KB	Share
EMD Becoming a substantial holder TAT
25/11/21		97.09KB	Share
EMD Notification regarding unquoted securities - EMD
24/11/21		29.1KB	Share
EMD Application for quotation of securities - EMD
24/11/21		26.5KB	Share
EMD Notice under section 708A(5)(e) of the Corporations Act
24/11/21		314.84KB	Share
EMD Emyria receives $1,162,000 R&D Tax Incentive Refund
24/11/21	PRICE SENSITIVE	141.05KB	Share
EMD Application for quotation of securities - EMD
22/11/21		26.69KB	Share
EMD Proposed issue of securities - EMD
22/11/21		28.34KB	Share
EMD Emyria Welcomes Tattarang as Strategic Investor
22/11/21	PRICE SENSITIVE	230.86KB	Share
EMD Trading Halt
19/11/21	PRICE SENSITIVE	702.94KB	Share
EMD Results of Meeting
03/11/21		146.11KB	Share
EMD Notification regarding unquoted securities - EMD
01/11/21		28.32KB	Share
EMD Appendix 4C - Quarterly
26/10/21	PRICE SENSITIVE	327.47KB	Share

REFRESH

First 2 3 4

Add to My Watchlist

What is My Watchlist?

A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.

(20min delay)
Last 4.9¢		Change 0.003(6.52%)		Mkt cap ! $29.96M

Open	High	Low	Value	Volume
4.7¢	5.1¢	4.6¢	$419.0K	8.556M

Buyers (Bids)

No.	Vol.	Price($)
1	26714	4.9¢

Sellers (Offers)

Price($)	Vol.	No.
5.0¢	180000	3

View Market Depth

No.	Vol.	Price($)
1	26714	0.049
1	4166	0.048
4	362367	0.047
4	236739	0.046
8	371234	0.045

Price($)	Vol.	No.
0.050	180000	3
0.051	100000	2
0.052	202777	3
0.053	36861	2
0.054	24000	1

Last trade - 16.10pm 31/07/2025 (20 minute delay)


Last 4.9¢		Change 0.003 ( 6.52 %)
Open	High	Low	Volume
4.7¢	5.0¢	4.6¢	2343943
Last updated 15.57pm 31/07/2025 ?

EMD (ASX) Chart

EMYRIA LIMITED - Announcements

Announcements

Buyers (Bids)

Sellers (Offers)

Infini Resources appoints Rohan Bone as CEO ahead of Phase 2 campaign

Resolution Minerals appoints industry experts to fast-track US growth strategy

A new NASDAQ listing for a key player in the global critical minerals space

Top Stories